Format

Send to

Choose Destination
World J Gastroenterol. 2016 May 21;22(19):4619-25. doi: 10.3748/wjg.v22.i19.4619.

HER2 testing in gastric cancer: An update.

Author information

1
Lucas Faria Abrahao-Machado, Cristovam Scapulatempo-Neto, Department of Pathology, Barretos Cancer Hospital, Barretos, SP 14784-400, Brazil.

Abstract

Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer. With the recent introduction of HER2 molecular targeted therapy for patients with advanced gastric cancer, determination of HER2 status is crucial in order to select patients who may benefit from this treatment. This paper provides an update on our knowledge of HER2 in gastric and gastroesophageal cancer, including the prognostic relevance of HER2, the key differences between HER2 protein expression interpretation in breast and gastric cancer, the detection methods and the immunohistochemistry scoring system.

KEYWORDS:

Gastric cancer; Human epidermal growth factor receptor 2 testing; Immunohistochemistry; Scoring system; Trastuzumab

PMID:
27217694
PMCID:
PMC4870069
DOI:
10.3748/wjg.v22.i19.4619
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center